Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eshwar Gumidyala

Psychiatry Crystal Lake, IL Medical Doctor

NPI 1891794137 CMS profile 86060

500 Coventry Ln, Suite 205, Crystal Lake, IL 60014

Open in the dashboard

General payments

$6,318

354 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eshwar Gumidyala of Crystal Lake, IL is reported in the CMS Open Payments database as having received $6,318 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $65 3
2024 General $36 2
2023 General $162 7
2022 General $1,426 77
2021 General $2,345 129
2020 General $1,027 57
2019 General $1,256 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eshwar Gumidyala
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Eshwar Gumidyala were reported at $65. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Eshwar Gumidyala Psychiatry median Middle half National median
2019 $1,256 $184 $59–$605 $163
2020 $1,027 $119 $36–$372 $114
2021 $2,345 $143 $43–$576 $132
2022 $1,426 $153 $50–$590 $149
2023 $162 $170 $56–$651 $160
2024 $36 $179 $57–$673 $164
2025 $65 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $919 62 payments
  2. Otsuka America Pharmaceutical, Inc. $825 53 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $659 31 payments
  4. Allergan Inc. $577 35 payments
  5. Neurocrine Biosciences, Inc. $430 21 payments
  6. Lundbeck LLC $323 18 payments
  7. Bausch Health US, LLC $284 15 payments
  8. Sunovion Pharmaceuticals Inc. $270 16 payments
  9. Janssen Pharmaceuticals, Inc $263 14 payments
  10. Avanir Pharmaceuticals, Inc. $259 15 payments
  11. Other $1,509 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,318 354 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $854 59 payments
  2. REXULTI $677 40 payments
  3. VRAYLAR Neuroscience $642 38 payments
  4. TRINTELLIX $497 20 payments
  5. ABILIFY MAINTENA $308 21 payments
  6. LATUDA $270 16 payments
  7. NUEDEXTA $259 15 payments
  8. APLENZIN $244 13 payments
  9. ARISTADA INITIO $238 12 payments
  10. ARISTADA $238 12 payments
  11. Other $3,595 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,010

Median for Psychiatry: 574

Drug cost

$45,251

Median for Psychiatry: $27,624

Branded share of claims

14.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aripiprazole Generic 57 $9,781
Divalproex Sodium Er Divalproex Sodium Brand 36 $5,458
Clozapine Generic 69 $5,031
Methylphenidate Er Methylphenidate Hcl Brand 17 $3,268
Quetiapine Fumarate Generic 161 $2,236
Bupropion Xl Bupropion Hcl Brand 140 $2,165
Escitalopram Oxalate Generic 153 $1,626
Olanzapine Generic 67 $1,323
Paliperidone Er Paliperidone Brand 13 $1,320
Risperidone Generic 137 $1,110

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$15,325

Medicare's payments for the services billed

Medicare patients

85

Average age 68

Services billed

300

52 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Depression 60%
Arthritis 34%
Diabetes 26%
Ischemic heart disease 22%
Chronic kidney disease 19%
Osteoporosis 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record